Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA Warns Against Misuse of Ketamine for Psychiatric Treatment

The FDA is wary of telemedicine prescriptions for ketamine that may be over-prescribing and failing to properly warn patients of risks.

Teresa Crawford
Teresa Crawford

The use of ketamine in psychiatric treatment is generally unapproved and unregulated, with the exception of esketamine, an FDA-approved ketamine nasal spray for treatment-resistant depression. According to a recent New York Times article, the FDA has raised concerns about the misuse of ketamine in treating psychiatric disorder.  The warning stems from reported adverse incidents, stressing that unsupervised use of ketamine elevates the risk of negative psychiatric reactions, heightened blood pressure, respiratory depression, and urinary tract problems, potentially leading to incontinence. 

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO